What is it about?
Review on epidemiological, microbiological, pharmacological, and clinical data on intravenous fosfomycin therapy against Pseudomonas.
Featured Image
Photo by CDC on Unsplash
Why is it important?
Multidrug-resistant Pseudomonas aeruginosa infections are increasingly common and very difficult to treat. By gathering in one place what is known about intravenous fosfomycin - how it works, how it reaches infected tissues, its action against biofilm and its synergy with other antibiotics - this review helps clinicians decide when and how to use this old drug as part of combination therapy.
Perspectives
Fosfomycin is an old molecule with a surprising second life. In our daily practice we often face Pseudomonas infections with very few therapeutic options, and I wanted to offer colleagues a practical, critical overview of when this drug can really make a difference.
Professor Stefano Di Bella
Universita degli Studi di Trieste
Read the Original
This page is a summary of: Intravenous Fosfomycin for Systemic Multidrug-Resistant Pseudomonas aeruginosa Infections, Antibiotics, November 2023, MDPI AG,
DOI: 10.3390/antibiotics12121653.
You can read the full text:
Contributors
The following have contributed to this page







